The prognostic significance of vasohibin-1 expression in patients with prostate cancer

Takeo Kosaka, Y. Miyazaki, A. Miyajima, Shuji Mikami, Yuichiro Hayashi, Nobuyuki Tanaka, H. Nagata, Eiji Kikuchi, K. Nakagawa, Y. Okada, Y. Sato, Mototsugu Oya

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background:We recently isolated vasohibin-1 (VASH1), a novel angiogenic molecule that is specifically expressed in activated vascular endothelial cells (ECs), and the status of VASH1 expression has been documented in various cancer angiogenesis. The aim of this study was to assess the prognostic value of VASH1 expression in prostate cancer (PCa).Methods:In this study, we retrospectively analysed the clinical records and evaluated the VASH1 expression of tumour microvessels in 167 patients with PCa who underwent radical prostatectomy. We immunohistochemically examined the microvessels positive for anti-CD34 as microvessel density (MVD) and the microvessels with activated ECs positive for VASH1 density.Results:We found that the VASH1 expression was restricted to ECs in the tumour stroma. VASH1 density was significantly associated with pathological T stage, Gleason score and MVD. The 5-year PSA recurrence-free survival rate was 58.8% in patients with higher VASH1 density (≧12 per mm 2) and 89.1% in patients with lower VASH1 density (<12 per mm 2), respectively (P<0.001). Microvessel density was not an independent predictor of PSA recurrence. Multivariate analysis revealed that high VASH1 density was an independent prognostic indicator of PSA recurrence (P=0.007, HR=2.950).Conclusion:VASH1 density represents a clinically relevant predictor of patient prognosis and can be a new biomarker that would provide additional prognostic information in PCa.

Original languageEnglish
Pages (from-to)2123-2129
Number of pages7
JournalBritish Journal of Cancer
Volume108
Issue number10
DOIs
Publication statusPublished - 2013 May

Fingerprint

Microvessels
Prostatic Neoplasms
Endothelial Cells
Recurrence
Neoplasms
Neoplasm Grading
Prostatectomy
Multivariate Analysis
Survival Rate
Biomarkers

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The prognostic significance of vasohibin-1 expression in patients with prostate cancer. / Kosaka, Takeo; Miyazaki, Y.; Miyajima, A.; Mikami, Shuji; Hayashi, Yuichiro; Tanaka, Nobuyuki; Nagata, H.; Kikuchi, Eiji; Nakagawa, K.; Okada, Y.; Sato, Y.; Oya, Mototsugu.

In: British Journal of Cancer, Vol. 108, No. 10, 05.2013, p. 2123-2129.

Research output: Contribution to journalArticle

Kosaka, Takeo ; Miyazaki, Y. ; Miyajima, A. ; Mikami, Shuji ; Hayashi, Yuichiro ; Tanaka, Nobuyuki ; Nagata, H. ; Kikuchi, Eiji ; Nakagawa, K. ; Okada, Y. ; Sato, Y. ; Oya, Mototsugu. / The prognostic significance of vasohibin-1 expression in patients with prostate cancer. In: British Journal of Cancer. 2013 ; Vol. 108, No. 10. pp. 2123-2129.
@article{39ed8fd7eed049358659a0598a4ee8bc,
title = "The prognostic significance of vasohibin-1 expression in patients with prostate cancer",
abstract = "Background:We recently isolated vasohibin-1 (VASH1), a novel angiogenic molecule that is specifically expressed in activated vascular endothelial cells (ECs), and the status of VASH1 expression has been documented in various cancer angiogenesis. The aim of this study was to assess the prognostic value of VASH1 expression in prostate cancer (PCa).Methods:In this study, we retrospectively analysed the clinical records and evaluated the VASH1 expression of tumour microvessels in 167 patients with PCa who underwent radical prostatectomy. We immunohistochemically examined the microvessels positive for anti-CD34 as microvessel density (MVD) and the microvessels with activated ECs positive for VASH1 density.Results:We found that the VASH1 expression was restricted to ECs in the tumour stroma. VASH1 density was significantly associated with pathological T stage, Gleason score and MVD. The 5-year PSA recurrence-free survival rate was 58.8{\%} in patients with higher VASH1 density (≧12 per mm 2) and 89.1{\%} in patients with lower VASH1 density (<12 per mm 2), respectively (P<0.001). Microvessel density was not an independent predictor of PSA recurrence. Multivariate analysis revealed that high VASH1 density was an independent prognostic indicator of PSA recurrence (P=0.007, HR=2.950).Conclusion:VASH1 density represents a clinically relevant predictor of patient prognosis and can be a new biomarker that would provide additional prognostic information in PCa.",
author = "Takeo Kosaka and Y. Miyazaki and A. Miyajima and Shuji Mikami and Yuichiro Hayashi and Nobuyuki Tanaka and H. Nagata and Eiji Kikuchi and K. Nakagawa and Y. Okada and Y. Sato and Mototsugu Oya",
year = "2013",
month = "5",
doi = "10.1038/bjc.2013.169",
language = "English",
volume = "108",
pages = "2123--2129",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - The prognostic significance of vasohibin-1 expression in patients with prostate cancer

AU - Kosaka, Takeo

AU - Miyazaki, Y.

AU - Miyajima, A.

AU - Mikami, Shuji

AU - Hayashi, Yuichiro

AU - Tanaka, Nobuyuki

AU - Nagata, H.

AU - Kikuchi, Eiji

AU - Nakagawa, K.

AU - Okada, Y.

AU - Sato, Y.

AU - Oya, Mototsugu

PY - 2013/5

Y1 - 2013/5

N2 - Background:We recently isolated vasohibin-1 (VASH1), a novel angiogenic molecule that is specifically expressed in activated vascular endothelial cells (ECs), and the status of VASH1 expression has been documented in various cancer angiogenesis. The aim of this study was to assess the prognostic value of VASH1 expression in prostate cancer (PCa).Methods:In this study, we retrospectively analysed the clinical records and evaluated the VASH1 expression of tumour microvessels in 167 patients with PCa who underwent radical prostatectomy. We immunohistochemically examined the microvessels positive for anti-CD34 as microvessel density (MVD) and the microvessels with activated ECs positive for VASH1 density.Results:We found that the VASH1 expression was restricted to ECs in the tumour stroma. VASH1 density was significantly associated with pathological T stage, Gleason score and MVD. The 5-year PSA recurrence-free survival rate was 58.8% in patients with higher VASH1 density (≧12 per mm 2) and 89.1% in patients with lower VASH1 density (<12 per mm 2), respectively (P<0.001). Microvessel density was not an independent predictor of PSA recurrence. Multivariate analysis revealed that high VASH1 density was an independent prognostic indicator of PSA recurrence (P=0.007, HR=2.950).Conclusion:VASH1 density represents a clinically relevant predictor of patient prognosis and can be a new biomarker that would provide additional prognostic information in PCa.

AB - Background:We recently isolated vasohibin-1 (VASH1), a novel angiogenic molecule that is specifically expressed in activated vascular endothelial cells (ECs), and the status of VASH1 expression has been documented in various cancer angiogenesis. The aim of this study was to assess the prognostic value of VASH1 expression in prostate cancer (PCa).Methods:In this study, we retrospectively analysed the clinical records and evaluated the VASH1 expression of tumour microvessels in 167 patients with PCa who underwent radical prostatectomy. We immunohistochemically examined the microvessels positive for anti-CD34 as microvessel density (MVD) and the microvessels with activated ECs positive for VASH1 density.Results:We found that the VASH1 expression was restricted to ECs in the tumour stroma. VASH1 density was significantly associated with pathological T stage, Gleason score and MVD. The 5-year PSA recurrence-free survival rate was 58.8% in patients with higher VASH1 density (≧12 per mm 2) and 89.1% in patients with lower VASH1 density (<12 per mm 2), respectively (P<0.001). Microvessel density was not an independent predictor of PSA recurrence. Multivariate analysis revealed that high VASH1 density was an independent prognostic indicator of PSA recurrence (P=0.007, HR=2.950).Conclusion:VASH1 density represents a clinically relevant predictor of patient prognosis and can be a new biomarker that would provide additional prognostic information in PCa.

UR - http://www.scopus.com/inward/record.url?scp=84878533977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878533977&partnerID=8YFLogxK

U2 - 10.1038/bjc.2013.169

DO - 10.1038/bjc.2013.169

M3 - Article

C2 - 23591203

AN - SCOPUS:84878533977

VL - 108

SP - 2123

EP - 2129

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 10

ER -